Health topic

Lung cancer

Supporting lung cancer patient management

Lung cancer is the second most common cancer in both men and women and the leading cause of cancer death worldwide, making up almost 25% of all cancer deaths.1 In the United States, approximately 1 in 16 people will be diagnosed with lung cancer in their lifetime. In 2021, the American Cancer Society estimates about 235,760 new cases of lung cancer and projects over 131,000 deaths.1

The right diagnostic information can help effectively manage patient care

Lung cancer is divided into two main subtypes, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Up to 85% of all lung cancers are NSCLC2, which can be further subtyped into adenocarcinoma, squamous cell carcinoma and large cell carcinoma.2 The need for accurate classification of these subtypes has been amplified with the introduction of targeted therapies.3

Targeted therapies have shifted the lung cancer treatment paradigm away from being based only on histological subtype, to incorporating subtyping involving oncogenic mutations and fusions.4

Lung cancer
Lung Cancer IHC portfolio

Roche Diagnostics lung cancer portfolio

Roche has developed a leading, comprehensive and differentiated lung cancer immunohistochemical portfolio, with biomarkers that support multiple guidelines for the diagnosis and stratification of lung cancers.5-7

  1. American Cancer Society (2021). Accessed May 2021.
  2. American Cancer Society (2021). What is Non-Small Cell Lung Cancer? Accessed May 2021.
  3. Tacha, D. et al (2012) A 6-antibody panel for the classification of lung adenocarcinoma versus squamous cell carcinoma. Appl Immunohistochem Mol Morphol. 2012;20:201-207.
  4. Pao, W. et al (2012) Chipping Away at the Lung Cancer Genome. Nature Medicine, 2012;18(3):349-351
  5. NCCN Clinical Practice Guidelines in Oncology Non-Small Cell Lung Cancer, Version 3.0 February 11, 2020, Accessed 5/01/20.
  6. National Comprehensive Cancer Network (2019). NCCN Guidelines Version 4.2019 Non-Small Cell Lung Cancer NCCN Evidence Blocks. Retrieved from Accessed 5th May 2019.
  7. Lindeman, N et al. (2018). Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors. Arch Pathol Lab Med. 142:321–346
Found 0 results in